Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Y0000341

Loperamide oxide monohydrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

trans-4-(4-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide 1-oxide monohydrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C29H33ClN2O3 · H2O
Numéro CAS:
106900-12-3
Poids moléculaire :
511.05
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

loperamide

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

Clc1ccc(cc1)C2(CC[N](=O)(CC2)CCC(c4ccccc4)(c3ccccc3)C(=O)N(C)C)O

InChI

1S/C29H33ClN2O3/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32(35)20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3

Clé InChI

KXVSBTJVTUVNPM-UHFFFAOYSA-N

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Loperamide oxide monohydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1370000

Loperamide hydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1162

Loperamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

L0750000

Loperamide hydrochloride, European Pharmacopoeia (EP) Reference Standard

1370065

Loperamide Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP635

Loperamide hydrochloride, British Pharmacopoeia (BP) Reference Standard

BP636

Loperamide N-oxide, British Pharmacopoeia (BP) Reference Standard

1370010

Loperamide System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

Y0002087

Loperamide for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR9195

4-(4-Chlorophenyl)-4-hydroxypiperidine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2916

Loperamide Related Compound F, pharmaceutical secondary standard, certified reference material

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301

Classification des risques

Acute Tox. 3 Oral

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

K Lavrijsen et al.
Drug metabolism and disposition: the biological fate of chemicals, 23(3), 354-362 (1995-03-01)
Loperamide oxide (LOPOX) is a prodrug of loperamide (LOP). The reduction of LOPOX to LOP was investigated to provide a pharmacokinetic basis for the pharmacodynamics and improved side effect profile of the prodrug. Reduction of LOPOX was studied in vitro
M van Outryve et al.
The Journal of international medical research, 23(5), 335-341 (1995-09-01)
Loperamide oxide was compared with placebo for the treatment of chronic diarrhoea in patients with Crohn's disease. After initially receiving 2 mg loperamide oxide or placebo, hospital out-patients with Crohn's disease were instructed to take one tablet of loperamide oxide
L E Van Beijsterveldt et al.
Drug metabolism and disposition: the biological fate of chemicals, 23(2), 216-222 (1995-02-01)
Loperamide oxide is a prodrug of the effective antidiarrheal loperamide. Administration of this prodrug improves efficacy and tolerability. For better understanding of these effects, the absorption and gastrointestinal distribution of loperamide oxide and of its active drug loperamide were studied.
Treatment of irritable bowel syndrome with loperamide oxide. An open study to determine optimal dosage.
G Ragnarsson et al.
Journal of internal medicine, 248(2), 165-166 (2000-08-18)
F Kamali et al.
European journal of clinical pharmacology, 42(6), 693-694 (1992-01-01)
The pharmacokinetics of loperamide, after oral administration of increasing doses (1 to 16 mg) of loperamide oxide, has been investigated in 10 healthy male volunteers, using a randomised cross-over design. Comparison of the maximum plasma loperamide concentration and AUC demonstrated
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique